Sientra (NASDAQ:SIEN) was downgraded by BidaskClub from a “hold” rating to a “sell” rating in a research report issued on Tuesday.
A number of other research firms have also recently weighed in on SIEN. Canaccord Genuity reaffirmed a “buy” rating and issued a $14.00 price objective on shares of Sientra in a report on Sunday, October 8th. Stifel Nicolaus reissued a “hold” rating and set a $14.00 target price (up previously from $11.00) on shares of Sientra in a research note on Wednesday, September 27th. Zacks Investment Research raised shares of Sientra from a “sell” rating to a “hold” rating in a research note on Tuesday, January 2nd. ValuEngine raised shares of Sientra from a “sell” rating to a “hold” rating in a research note on Sunday, December 31st. Finally, William Blair raised shares of Sientra from a “market perform” rating to an “outperform” rating in a research note on Wednesday, September 13th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus target price of $15.00.
Sientra (NASDAQ SIEN) traded down $0.08 during mid-day trading on Tuesday, hitting $13.15. 90,700 shares of the company were exchanged, compared to its average volume of 162,057. The company has a debt-to-equity ratio of 0.57, a quick ratio of 1.92 and a current ratio of 2.87. Sientra has a 1-year low of $7.20 and a 1-year high of $16.68. The firm has a market cap of $241.67, a PE ratio of -4.61 and a beta of -1.47.
Sientra (NASDAQ:SIEN) last released its quarterly earnings data on Tuesday, November 7th. The medical instruments supplier reported ($0.74) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.68) by ($0.06). Sientra had a negative return on equity of 68.82% and a negative net margin of 169.77%. The firm had revenue of $9.80 million during the quarter, compared to analyst estimates of $10.54 million. During the same period last year, the business earned ($0.55) EPS. The firm’s revenue was up 50.8% on a year-over-year basis. analysts expect that Sientra will post -3.23 earnings per share for the current fiscal year.
A number of institutional investors have recently added to or reduced their stakes in SIEN. Bamco Inc. NY increased its stake in Sientra by 109.3% during the 2nd quarter. Bamco Inc. NY now owns 471,500 shares of the medical instruments supplier’s stock valued at $4,583,000 after buying an additional 246,183 shares during the period. EAM Investors LLC bought a new position in shares of Sientra during the 3rd quarter valued at about $3,018,000. Pura Vida Investments LLC bought a new position in shares of Sientra during the 3rd quarter valued at about $2,892,000. State Street Corp bought a new position in shares of Sientra during the 2nd quarter valued at about $1,449,000. Finally, Northern Trust Corp boosted its position in shares of Sientra by 449.4% during the 2nd quarter. Northern Trust Corp now owns 149,227 shares of the medical instruments supplier’s stock valued at $1,451,000 after purchasing an additional 122,066 shares in the last quarter. 76.63% of the stock is currently owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: This report was originally reported by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://www.dispatchtribunal.com/2018/01/11/sientra-sien-stock-rating-lowered-by-bidaskclub.html.
Sientra Company Profile
Sientra, Inc is a medical aesthetics company. The Company’s primary products are silicone gel breast implants for use in breast augmentation and breast reconstruction procedures, which it offers in over 190 variations of shapes, sizes and textures. The Company sells its breast implants and breast tissue expanders, or breast products to plastic surgeons.
Receive News & Ratings for Sientra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sientra and related companies with MarketBeat.com's FREE daily email newsletter.